The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas

Expert Opinion on Biological Therapy

Volumn 7, Issue 11, 2007, Pages 1749-1762

  Jacobs, Samuel A ^a   Foon, Kenneth A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD20 therapy; B cell lymphomas; Immunotherapy; Monoclonal antibody therapy; Radioimmunotherapy; Rituximab

Indexed keywords

MONOCLONAL ANTIBODY; RITUXIMAB; ANTINEOPLASTIC AGENT;

B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; FOLLICULAR LYMPHOMA; HUMAN; MANTLE CELL LYMPHOMA; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; ANIMAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY;

EID: 36048975078     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.11.1749     Document Type: Review

References (53)

1. PARKER SL, TONG T, BOLDEN S, WINGO PA: Cancer statistics, 1996. CA Cancer J. Clin. (1996) 46(1):5-27.
2. MÜLLER AMS, IHORST G, MERTELSMANN R, ENGELHARDT M: Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann. Hematol. (2005) 84:1-12.
3. AISENBERG AC: Coherent view of non-Hodgkin's lymphoma. J. Clin. Oncol (1995) 13(10):2656-2675.
4. EDWARDS BK, BROWN ML, WINGO PA et al.: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. (2005) 97(19):1407-1427.
5. WORLD HEALTH ORGANIZATION: Classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France (2001).
6. CARTRON G, WATIER H, GOLAY J, SOLAL-CELIGNY P: From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 104:2635-2642.
7. GOLAY JT, CLARK EA, BEVERLEY PC: The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J. Immunol. (1985) 135:3795-3801.
8. IDEC PHARMACEUTICALS: Yttrium-[90] ibritumomab tiuxetan (Zevalin™; IDEC-Y2B8) radioimmunotherapy regimen. Investigational Brochure. 6th Edition (2001).
9. REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435-445.
10. GOLAY J, LAZZARI M, FACCHINETTI V et al.: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 98:3383-3389.
11. GOLAY J, ZAFFARONI L, VACCARI T et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95:3900-3908.
12. TREON SP, MITSIADES C, MITSIADES N et al.: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. (2001) 24(3):263-271.
13. CARTRON G, DACHEAUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FeYRIIIa gene. Blood (2002) 99:754-758.
14. WENG WK, LEVY R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. (2003) 21:3940-3947.
15. WENG WK, LEVY R: Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in vollicular non-Hodgkin's lymphoma. Blood (2002) 100 (Abstract).
16. KAUFMANN H, RAFIQ K, WOHRER S et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood (2004) 104(8):2269-2271.
17. BONAVIDA B: Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene (2007) 26(25):3629-3636.
18. BYRD JC, KITADA S, FLINN IW et al.: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evicence of caspase activation and apoptosis induction. Blood (2002) 99(3):1038-1043.
19. CHAN HT, HUGHES D, FRENCH RR et al.: CD20-induced lymphoma cell death is independent of both caspases and its redistribution into tritonX-100 insoluale membrane rafts. Cancer Res. (2003) 63(17):5480-5489.
20. VAN DER KOLK LE, EVERS LM, OMENE CL et al.: CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia (2002) 16(9):1735-1744.
21. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood (2000) 96:1259-1266.
22. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int. J. Oncol. (1999) 15:1017-1025.
23. JOHNSTON PB, BONDLY C, MICALLEF I: Ibritumomab tiuxetan for non-Hodgkin's lymphoma. Expert Rev. Anticancer Ther. (2006) 6(6):861-869.
24. 90Y-ibritumomab tiuxetan (Zevalin®). J. Exp. Ther. Oncol. (2004) 4:305-316.
25. 90Y) ibritumomab tiuxetan (Zevalin®) in a patient with low-grade non-Hodgkin's lymphoma (NHL). Blood (2004) 104(11).
26. LOSSOS IS, LEVY R: Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood (2000) 96(2):635-639.
27. KORSMEYER SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood (1992) 80(4):879-886.
28. SOLAL-CÉLIGNY P, ROY P, COLOMBAT P et al.: Follicular lymphoma international prognostic index. Blood (2004) 104(5):1258-1265.
29. KÜPPERS R: Prognosis in follicular lymphoma - it's in the microenvironment. N. Engl. J. Med. (2004) 351(21):2152-2153.
30. DAVE SS, WRIGHT G, TAN B et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. (2004) 351(21):2159-2167.
31. FISHER RI, LEBLANC M, PRESS OW, MALONEY DG, UNGER JM, MILLER TP: New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. (2005) 23(33):8447-8452.
32. MALONEY DG, GRILLO-LOPEZ AJ, BODKIN DJ et al.: IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15(10):3266-3274.
33. MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16(8):2825-2833.
34. COLOMBAT P, SALLES G, BROUSSE N et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood (2001) 97(1):101-106.
35. PIRO LD, WHITE CA, GRILLO-LOPEZ AJ et al.: Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1999) 10(6):655-661.
36. HAINSWORTH JD, LITCHY S, BURRIS HA III et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J. Clin. Oncol. (2002) 20(20):4261-4267.
37. HAINSWORTH JD, BURRIS HA III, MORISSEY LH et al.: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood (2000) 95(10):3052-3056.
38. GORDAN LN, GROW WB, PUSATERI A, DOUGLAS V, MENDENHALL NP, LYNCH JW: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J. Clin. Oncol. (2005) 23(6):1096-1102.
39. The efficacy of rituximab plus hyper-CVAD regimen in mantle cell lymphoma is independent of FCγRIIIa and FCγRIIa polymorphisms
40. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J Med. (2005) 352:441-449.
41. CZUCZMAN M, GRILLO-LOPEZ AJ, MCLAUGHLIN P, WHITE CA: Clearing of cells bearing the bcl-2 [t(14; 18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol. (2001) 12:109-114.
42. CZUCZMAN MS, WEAVER R, ALKUZWENY B, BERLFEIN J, GRILLO-LOPEZ AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. (2004) 22(23):4711-4716.
43. CZUCZMAN MS, KORYZNA A, MOHR A et al.: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. (2005) 23(4):694-704.
44. FORSTPOINTNER R, DREYLING M, REPP R et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood (2004) 104(10):3064-3071.
45. FORSTPOINTNER R, UNTERHALT M, DREYLING M et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle call lymphomas: results of a prospective randomized study of the Greman low grade lymphoma study group (GLSG). Blood (2006) 108(13):4003-4008.
46. HOCHSTER HS, WELLER E, RYAN T et al.: Results of E1496: A Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J. Clin. Oncol. (2004) 22(14S) (Abstract).
47. HOCHSTER HS, WELLER E, GASCOYNE RD et al.: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 Phase III trial from the Eastern cooperative oncology group and the cancer and leukemia group B. Blood (2005) 106(11):A106 (Abstract).
48. MARCUS R, IMRIE K, BELCH A et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2005) 105(4):1417-1423.
49. HIDDEMANN W, KNEBA M, DREYLING M et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood (2005) 106(12):3725-3732.
50. PRESS OW, UNGER JM, BRAZIEL RM et al.: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphomna: five-year follo-up of Southwest oncology group protocol S9911. J. Clin. Oncol. (2006) 24(25):4143-4149.
51. LEONARD JP, COLEMAN M, KOSTAKOBLU L et al.: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J. Clin. Oncol. (2005) 23(24):5696-5704.
52. LINK B, KAMINSKI MS, COLEMAN M, LEONARD JP: Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J. Clin. Oncol. (2004) 22(14S) (Abstract).
53. 90Y-ibritumomab tiuxetan as first-line treatment for patients with follocular lymphoma: a minnie pearl cancer research network Phase II trial. J. Clin. Oncol. (2004) 22(14S) (Abstract).